Dipotassium phosphate

Identification

Summary

Dipotassium phosphate is an ionic compound used for electrolyte replenishment and total parenteral nutrition (TPN) therapy.

Brand Names

Clinimix E 2.75/5, Isolyte P

Generic Name

Dipotassium phosphate

DrugBank Accession Number

DB09414

Background

Dipotassium phosphate (K2HPO4) is a highly water-soluble salt often used as a fertilizer and food additive as a source of phosphorus and potassium as well as a buffering agent.

Type

Small Molecule

Groups

Approved

Structure

Download

MOLSDFPDBSMILESInChI

Similar Structures

Structure for Dipotassium phosphate (DB09414)

×

Close

Weight

Average: 174.1759
Monoisotopic: 173.888658754

Chemical Formula

HK₂O₄P

Synonyms

• Di-potassium hydrogen phosphate
• Dibasic potassium phosphate
• Dipotassium acid phosphate
• Dipotassium hydrogen monophosphate
• Dipotassium hydrogen orthophosphate
• Dipotassium hydrogen phosphate
• Dipotassium monophosphate
• Kali phosphoricum
• Phosphoric acid, dipotassium salt
• Phosphoric acid, potassium salt (1:2)
• Potassium phosphate dibasic
• Potassium phosphate, dibasic
• Potassium phosphate,dibasic
• Secondary potassium phosphate

External IDs

• 231-834-5
• E-340(II)
• INS no.340(II)
• INS-340(II)

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

Dipotassium phosphate is used in imitation dairy creamers, dry powder beverages, mineral supplements, and starter cultures as an additive. It is used in non-dairy creamers to prevent coagulation. Dipotassium phosphate is also used to make buffer solutions and it is used in the production of trypticase soy agar which is used to make agar plates for culturing bacteria.

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Age Group	Patient Characteristics	Dose Form
Used in combination to treat	Electrolyte imbalance	Combination Product in combination with: Potassium chloride (DB00761), Sodium acetate (DB09395), Dextrose, unspecified form (DB09341), Magnesium chloride (DB09407)	••••••••••••		•••••••• ••••••• ••••••	•••••••••
Used in combination to treat	Mild metabolic acidosis	Combination Product in combination with: Sodium acetate (DB09395), Potassium chloride (DB00761), Magnesium chloride (DB09407), Dextrose, unspecified form (DB09341)	••••••••••••			•••••••••

Create Account

Associated Therapies

• Fluid replacement therapy
• Parenteral rehydration therapy
• Total parenteral nutrition therapy
• Urine alkalinization therapy
• Fluid and electrolyte maintenance therapy

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Phosphate is a major intracellular anion which participates in providing energy for metabolism of substances and contributes to important metabolic and enzymatic reactions in almost all organs and tissues. Phosphate exerts a modifying influence on calcium concentrations, a buffering effect on acid-base equilibrium, and has a major role in the renal excretion of hydrogen ions.

Mechanism of action

Once phosphate gains access to the body fluids and tissues, it exerts little pharmacological effect. If the ion is introduced into the intestine, the absorbed phosphate is rapidly excreted. If large amounts are given by this route, much of it may escape absorption. Because this property leads to a cathartic action, phosphate salts are employed as mild laxatives.

Absorption

Potassium salts are well absorbed from gastro intestinal tract. Net phosphorus absorption may occur in the small intestine in some species but is primarily a function of the colon in horses.

Volume of distribution

Distribution is largely intracellular, but it is the intravascular concentration that is primarily responsible for toxicity.

Protein binding

Phosphate is minimally protein bound, and highly concentrated in cells (intracellular concentrations are 100-fold higher than serum concentrations). Concentrations of phosphate in plasma are higher in children than in adults.

Metabolism

Phosphate is a major intracellular anion which participates in providing energy for metabolism of substances and contributes to important metabolic and enzymatic reactions in almost all organs and tissues.

Route of elimination

Potassium is excreted primarily by kidney.

Half-life

In healthy children with phosphate overdose, half-life was 4.8 to 10.6 hours, and was prolonged to 17 hours in a child with renal insufficiency.

Clearance

Phosphates are rapidly cleared by dialysis.

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

LD50 not available. Toxic effects in humans: Irritated skin, eye. Gastro intestinal irritation with nausea, vomiting, diarrhea, abdominal discomfort

Pathways

Not Available

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Acebutolol	Dipotassium phosphate may increase the hyperkalemic activities of Acebutolol.
Aceclofenac	Dipotassium phosphate may increase the hyperkalemic activities of Aceclofenac.
Acemetacin	Dipotassium phosphate may increase the hyperkalemic activities of Acemetacin.
Acetazolamide	The risk or severity of dehydration can be increased when Acetazolamide is combined with Dipotassium phosphate.
Acetylsalicylic acid	Dipotassium phosphate may increase the hyperkalemic activities of Acetylsalicylic acid.

Food Interactions

No interactions found.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Active Moieties

Name	Kind	UNII	CAS	InChI Key
Potassium cation	ionic	295O53K152	24203-36-9	NPYPAHLBTDXSSS-UHFFFAOYSA-N
Phosphate ion	ionic	NK08V8K8HR	14265-44-2	NBIIXXVUZAFLBC-UHFFFAOYSA-K

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
2.5% Travasol Amino Acid Injection With Electrolytes In 10% Dextrose	Dipotassium phosphate (130.5 mg / 100 mL) + Alanine (520 mg / 100 mL) + Arginine (290 mg / 100 mL) + Dextrose, unspecified form (10 g / 100 mL) + Glycine (260 mg / 100 mL) + Histidine (120 mg / 100 mL) + Isoleucine (150 mg / 100 mL) + Leucine (182.5 mg / 100 mL) + Lysine hydrochloride (145 mg / 100 mL) + Magnesium chloride (25.5 mg / 100 mL) + Methionine (100 mg / 100 mL) + Phenylalanine (140 mg / 100 mL) + Proline (170 mg / 100 mL) + Serine (125 mg / 100 mL) + Sodium acetate (170 mg / 100 mL) + Sodium chloride (29.3 mg / 100 mL) + Threonine (105 mg / 100 mL) + Tryptophan (45 mg / 100 mL) + Tyrosine (10 mg / 100 mL) + Valine (145 mg / 100 mL)	Solution	Intravenous	Baxter Corporation Clintec Nutrition Division	1996-12-31	2015-08-05
2.5% Travasol Amino Acid Injection With Electrolytes In 10% Dextrose Clinimix	Dipotassium phosphate (130.5 mg / 100 mL) + Alanine (520 mg / 100 mL) + Arginine (260 mg / 100 mL) + Dextrose, unspecified form (10 g / 100 mL) + Glycine (520 mg / 100 mL) + Histidine (110 mg / 100 mL) + Isoleucine (120 mg / 100 mL) + L-Leucine hydrochloride (155 mg / 100 mL) + Lysine hydrochloride (145 mg / 100 mL) + Magnesium chloride (25.5 mg / 100 mL) + Methionine (145 mg / 100 mL) + Phenylalanine hydrochloride (155 mg / 100 mL) + Proline (105 mg / 100 mL) + Sodium acetate (170 mg / 100 mL) + Sodium chloride (29.3 mg / 100 mL) + Threonine (105 mg / 100 mL) + Tryptophan (45 mg / 100 mL) + Tyrosine (10 mg / 100 mL) + Valine (115 mg / 100 mL)	Solution	Intravenous	Baxter Corporation Clintec Nutrition Division	1993-12-31	2015-08-05
2.5%travasol Amino Acid InJ.W.eleC.W.25%dex	Dipotassium phosphate (130.5 mg / 100 mL) + Alanine (520 mg / 100 mL) + Arginine (290 mg / 100 mL) + Dextrose, unspecified form (25 g / 100 mL) + Glycine (260 mg / 100 mL) + Histidine (120 mg / 100 mL) + Isoleucine (150 mg / 100 mL) + Leucine (182.5 mg / 100 mL) + Lysine hydrochloride (145 mg / 100 mL) + Magnesium chloride (25.5 mg / 100 mL) + Methionine (100 mg / 100 mL) + Phenylalanine (140 mg / 100 mL) + Proline (170 mg / 100 mL) + Serine (125 mg / 100 mL) + Sodium acetate (170 mg / 100 mL) + Sodium chloride (29.3 mg / 100 mL) + Threonine (105 mg / 100 mL) + Tryptophan (45 mg / 100 mL) + Tyrosine (10 mg / 100 mL) + Valine (145 mg / 100 mL)	Liquid	Intravenous	Clintec Nutrition Company	1996-07-30	1998-08-13
2.75% Travas. Amino Acid InJ.W.elecw.25%dex	Dipotassium phosphate (261 mg / 100 mL) + Alanine (570 mg / 100 mL) + Arginine (316 mg / 100 mL) + Dextrose, unspecified form (25 g / 100 mL) + Glycine (283 mg / 100 mL) + Histidine (132 mg / 100 mL) + Isoleucine (165 mg / 100 mL) + Leucine (201 mg / 100 mL) + Lysine hydrochloride (159.5 mg / 100 mL) + Magnesium chloride (51 mg / 100 mL) + Methionine (110 mg / 100 mL) + Phenylalanine (154 mg / 100 mL) + Proline (187 mg / 100 mL) + Serine (137.5 mg / 100 mL) + Sodium acetate (215.5 mg / 100 mL) + Sodium chloride (112 mg / 100 mL) + Threonine (115.5 mg / 100 mL) + Tryptophan (49.5 mg / 100 mL) + Tyrosine (11 mg / 100 mL) + Valine (159.5 mg / 100 mL)	Liquid	Intravenous	Clintec Nutrition Company	1996-07-30	1998-08-13
2.75% Travasol Amino Acid Injection With Electrolytes In 25% Dextrose Quickmix	Dipotassium phosphate (261 mg / 100 mL) + Alanine (570 mg / 100 mL) + Arginine (285 mg / 100 mL) + Dextrose, unspecified form (25 g / 100 mL) + Glycine (570 mg / 100 mL) + Histidine (120.5 mg / 100 mL) + Isoleucine (131.5 mg / 100 mL) + L-Leucine hydrochloride (170 mg / 100 mL) + Lysine hydrochloride (159 mg / 100 mL) + Magnesium chloride (51 mg / 100 mL) + Methionine (159 mg / 100 mL) + Phenylalanine hydrochloride (170 mg / 100 mL) + Proline (115 mg / 100 mL) + Sodium acetate (215.5 mg / 100 mL) + Sodium chloride (112 mg / 100 mL) + Threonine (115 mg / 100 mL) + Tryptophan (49.5 mg / 100 mL) + Tyrosine (11 mg / 100 mL) + Valine (126 mg / 100 mL)	Solution	Intravenous	Baxter Corporation Clintec Nutrition Division	1996-02-02	2007-08-02

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Clinimix	Dipotassium phosphate (2.61 g/1L) + Alanine (5.70 g/1L) + Arginine (3.17 g/1L) + Calcium chloride dihydrate (0.33 g/1L) + D-glucose monohydrate (100.00 g/1L) + Glycine (2.84 g/1L) + Histidine (1.32 g/1L) + Isoleucine (1.65 g/1L) + Leucine (2.01 g/1L) + Lysine (2.00 g/1L) + Magnesium chloride hexahydrate (0.51 g/1L) + Methionine (1.10 g/1L) + Phenylalanine (1.54 g/1L) + Proline (1.87 g/1L) + Serine (1.38 g/1L) + Sodium acetate trihydrate (2.16 g/1L) + Sodium chloride (1.12 g/1L) + Threonine (1.16 g/1L) + Tryptophan (0.50 g/1L) + Tyrosine (0.11 g/1L) + Valine (1.60 g/1L)	Solution	Intravenous	Baxter Healthcare Corporation	2017-10-25	2019-11-30
Clinimix	Dipotassium phosphate (5.22 g/2L) + Alanine (17.60 g/2L) + Arginine (9.78 g/2L) + Calcium chloride dihydrate (0.66 g/2L) + D-glucose monohydrate (300.00 g/2L) + Glycine (8.76 g/2L) + Histidine (4.08 g/2L) + Isoleucine (5.10 g/2L) + Leucine (6.20 g/2L) + Lysine (4.93 g/2L) + Magnesium chloride hexahydrate (1.02 g/2L) + Methionine (3.40 g/2L) + Phenylalanine (4.76 g/2L) + Proline (5.78 g/2L) + Serine (4.25 g/2L) + Sodium acetate trihydrate (5.94 g/2L) + Sodium chloride (1.54 g/2L) + Threonine (3.57 g/2L) + Tryptophan (1.53 g/2L) + Tyrosine (0.34 g/2L) + Valine (4.93 g/2L)	Solution	Intravenous	Baxter Healthcare Corporation	2017-10-25	2019-11-30
Clinimix	Dipotassium phosphate (2.61 g/1L) + Alanine (5.70 g/1L) + Arginine (3.17 g/1L) + Calcium chloride dihydrate (0.33 g/1L) + D-glucose monohydrate (75.00 g/1L) + Glycine (2.84 g/1L) + Histidine (1.32 g/1L) + Isoleucine (1.65 g/1L) + Leucine (2.01 g/1L) + Lysine (2.00 g/1L) + Magnesium chloride hexahydrate (0.51 g/1L) + Methionine (1.10 g/1L) + Phenylalanine (1.54 g/1L) + Proline (1.87 g/1L) + Serine (1.38 g/1L) + Sodium acetate trihydrate (2.16 g/1L) + Sodium chloride (1.12 g/1L) + Threonine (1.16 g/1L) + Tryptophan (0.50 g/1L) + Tyrosine (0.11 g/1L) + Valine (1.60 g/1L)	Solution	Intravenous	Baxter Healthcare Corporation	2017-10-25	2019-11-30
ISOLYTE M PVC 500 ML(SETLI)	Dipotassium phosphate (0.13 %) + D-glucose monohydrate (5 %) + Potassium chloride (0.15 %) + Sodium acetate trihydrate (0.28 %) + Sodium chloride (0.091 %)	Solution	Intravenous	ECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş.	2017-05-23	2024-01-23
ISOLYTE M PVC 500 ML(SETSIZ)	Dipotassium phosphate (0.13 %) + D-glucose monohydrate (5 %) + Potassium chloride (0.15 %) + Sodium acetate trihydrate (0.28 %) + Sodium chloride (0.091 %)	Solution	Intravenous	ECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş.	2017-05-23	2024-01-23

Categories

Drug Categories

• Acids
• Acids, Noncarboxylic
• Anions
• Buffers
• Cariostatic Agents
• Compounds used in a research, industrial, or household setting
• Dental Materials
• Electrolytes
• Ions
• Laboratory Chemicals
• Laxatives
• Phosphate salts
• Phosphoric Acids
• Phosphorus Acids
• Phosphorus Compounds
• Potassium Salt
• Protective Agents

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of inorganic compounds known as alkali metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is an alkali metal.

Kingdom

Inorganic compounds

Super Class

Mixed metal/non-metal compounds

Class

Alkali metal oxoanionic compounds

Sub Class

Alkali metal phosphates

Direct Parent

Alkali metal phosphates

Alternative Parents

Inorganic salts / Inorganic oxides

Substituents

Alkali metal phosphate / Inorganic oxide / Inorganic salt

Molecular Framework

Not Available

External Descriptors

organic molecular entity (CHEBI:32031)

Affected organisms

Not Available

Chemical Identifiers

UNII

CI71S98N1Z

CAS number

7758-11-4

InChI Key

ZPWVASYFFYYZEW-UHFFFAOYSA-L

InChI

InChI=1S/2K.H3O4P/c;;1-5(2,3)4/h;;(H3,1,2,3,4)/q2*+1;/p-2

IUPAC Name

dipotassium hydrogen phosphate

SMILES

[K+].[K+].OP([O-])([O-])=O

References

General References

1. Pubchem [Link]
2. Toxnet [Link]
3. MSDS [Link]

External Links

KEGG Compound

C13197

PubChem Compound

24450

PubChem Substance

347827847

ChemSpider

22858

RxNav

55018

ChEBI

131527

ChEMBL

CHEMBL1200459

Wikipedia

Dipotassium_phosphate

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
2, 3	Terminated	Treatment	Dry Mouth	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Injection, solution	Intravenous
Liquid	Buccal
Solution	Intravenous
Spray	Oral
Aerosol, spray	Oral
Liquid	Intravesical
Solution	Intravenous	0.775 g
Powder	Oral
Tablet	Oral
Injection, solution, concentrate	Intravenous
Solution, concentrate	Intravenous
Liquid	Intravenous
Aerosol	Oral
Injection	Intravenous
Powder, for solution	Oral
Liquid	Oral
Solution	Intravenous	87.1 mg/1ml

Prices

Not Available

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)	Region
US10632150	No	2020-04-28	2039-04-19

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
logP	-1	Chemaxon
pKa (Strongest Acidic)	1.8	Chemaxon
Physiological Charge	-2	Chemaxon
Hydrogen Acceptor Count	4	Chemaxon
Hydrogen Donor Count	1	Chemaxon
Polar Surface Area	83.42 Å2	Chemaxon
Rotatable Bond Count	0	Chemaxon
Refractivity	12.41 m3·mol-1	Chemaxon
Polarizability	5.24 Å3	Chemaxon
Number of Rings	0	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	splash10-00di-0900000000-c5611637681caf053d69

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å2)	Source type	Source
[M-H]-	109.98364	predicted	DeepCCS 1.0 (2019)
[M+H]+	113.01175	predicted	DeepCCS 1.0 (2019)
[M+Na]+	121.87001	predicted	DeepCCS 1.0 (2019)

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at November 30, 2015 19:10 / Updated at June 12, 2020 16:52